Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase

Journal of Neural Transmission

Volumn 119, Issue 4, 2012, Pages 405-414

  Inaba Hasegawa, Keiko ^a   Akao, Yukihiro ^b   Maruyama, Wakako ^c   Naoi, Makoto ^a  

^a GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

( )Deprenyl; Bcl 2; Gene induction; Neuroprotection; Rasagiline; Type A and B monoamine oxidase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BEFLOXATONE; MESSENGER RNA; PROTEIN; PROTEIN BCL 2; RASAGILINE; SELEGILINE; SMALL INTERFERING RNA;

ARTICLE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROPROTECTION; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; WILD TYPE;

ANALYSIS OF VARIANCE; CELL LINE, TUMOR; CYCLOHEXIMIDE; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDANS; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROBLASTOMA; OXAZOLES; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SELEGILINE; TRANSFECTION; UP-REGULATION;

EID: 84863468762     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0730-6     Document Type: Article

References (41)

1. Abu-Raya S, Tabakman R, Blaugrund E, Trembovier V, Lazaroyici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434:109-116
2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (2002) An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326:105-108
3. Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J Med Chem 48:8148-8154
4. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64:113-127
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72:248-254
6. Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, Ho LL-T, Lee CH, Chang YL (2006) Moclobemide upregulated Bcl-2 expression and induce neural stem cell differentiation into serotoninergic neurons via extracellular-regulated kinase pathway. Br J Pharmacol 148:587-598
7. Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion 9:289-298
8. De Zutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98:6168-6173
9. Desagher S, Osen-Sand A, Nichols A, Eskes R, Monteaauit S, Lauper S, Maundrell K, Antonsson B, Martinou J-C (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891-901
10. Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, ReFacy HE, Carlson EC (2006) Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7:1513-1529
11. Ekblom J, Oreland L, Chen K, Shih JC (1998) Is there a "non-MAO" macromolecular target for L-deprenyl?: Studies on MAOB mutant mice. Life Sci 63:PL161-PL186
12. Finberg JP, Lamendorf I, Weinstock M, Schwartz M, Youdim MBH (1999) Pharmacology of rasagiline [N-propargyl-1R-aminoindan]. Adv Neurol 80:495-499
13. Fitzgerald JC, Ufer C, Billett EE (2007) A link between monoamine oxidase-A and apoptosis in serum derived human SH-SY5Y cells. J Neural Transm 114:807-810
14. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469
15. Hubalek F, Binda C, Ki M, Herzig Y, Sterling J, Youdim MBH, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and its analogues. J Med Chem 47:1760-1768
16. Hynson RMG, Kelly SM, Price NC, Ramsay RR (2004) Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophy Acta 1472:60-66
17. Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, Heinsen H, Beckmann H (1989) Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 499:81-86
18. Kraml M (1965) A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14:1684-1686
19. Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P, Gerlach M, Oertel WH (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the nonhuman primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 108:985-1009
20. Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szöko E (2004) Pharmacological aspects of (-)-deprenyl. Curr Med Chem 11:2017-2031
21. Malorni W, Giammarioli P, Pietrangeli E, Agostinelli E, Ciaccio A, Grassili E, Mondove B (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426:155-159
22. Maragos WF, Tillman PA, Chesnut MD, Jakel RJ (1999) Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834:168-172
23. Maruyama W, Takahashi T, Naoi M (1998) (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70:2510-2515
24. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727-735
25. Maruyama W, Takahashi T, Youdim M, Naoi M (2002) The anti- Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109:467-481
26. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-jB transcription factor. Neurochem Int 44:393-400
27. Naoi M, Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 9:1233-1250
28. Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharmaceu Designs 16:2799-2817
29. Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm (71):67-77
30. Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Eng J Med 361:1268-1278
31. Ou X-M, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103:10923-10928
32. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R, Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200-1206
33. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on progression of disability in early Parkinson's disease. N Engl J Med 328:176-183
34. Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033-2043
35. Shacka JJ, Roth KA (2005) Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 4:24-39
36. Tatton WG, Ju WYL, Holland D, Tai C, Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572-1575
37. Tazik S, Johnson S, Lu D, Johnson C, Youdim MBH, Stockmeler CA, Ou X-M (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotoxic Res 15:284-290
38. Yi H, Akao Y, Maruyama W, Chen K, Shih JC, Naoi M (2006a) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96:541-549
39. Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M (2006b) N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R) salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113:21-32
40. Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309
41. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MBH, Le W (2008) Comparison of neuroprotective and neurorestorative capacities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopamine degeneration. J Neurochem 105:1970-1978